Bluerock Acquisition Corp. II completed its initial public offering of 17.25 million units at $10 each, raising $172.5 million, including the full exercise of the underwriter's over-allotment option. Each unit includes one Class A share and half a warrant, with warrants exercisable at $11.50 per share. The units began trading on Nasdaq under the ticker BRRKU on September 25, 2026, with shares and warrants expected to trade separately later. The company also closed a private placement of 5.8 million warrants, raising an additional $5.8 million. Bluerock Acquisition II is a blank check company aiming to merge with or acquire businesses in any industry, targeting companies at growth inflection points seeking strategic capital partners.
Bluerock Acquisition Corp. II announced the closing of its $172.5 million initial public offering, including full exercise of the underwriter's over-allotment option. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 29, 2026 00:41 WIB: out of 85 priced US Financials stocks, 11 rose and 73 fell. Notable movers include NU (Nu Holdings Ltd) at USD 12.39 with a 1-day change of -8.83% and a typical hold time on Pluang of 53 days, GEMI (Gemini Space Station Inc) at USD 5.28 down 4.69% with a 13-day hold, and LU (Lufax Holding Ltd) at USD 1.28 up 4.47% with a 12-day hold time.
The Cardano Foundation has formed a multi-year partnership with UCLA Anderson School of Management to integrate blockchain education and startup support on campus. Starting in 2027, Cardano Academy content will be part of a UCLA blockchain course, an...
San Juan Basin Royalty Trust, managed by Argent Trust Company, provided updates on administrative expenses, audit adjustments, and liquidity. The Trust reported a $976,000 decrease in expenses due to the 2024 trustee transition and changes in audit c...
The XDC token of the XDC Network saw gains over a 24-hour period, ranking among the top three gainers by market cap with about $719 million. Increased derivatives activity, including an 18% rise in open interest to $7.12 million and a positive fundin...
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Hedera Hashgraph (HBAR) rallied 26% to around $0.13 following significant developments from IBM and BlackRock. IBM listed the HBAR-IDTrust platform on its cloud catalog, enhancing enterprise access to identity infrastructure for agents and devices. M...
